We are delighted to welcome Dr Dan Zurawski of @genevaUSA and Triari Pharmaceuticals into the #PACEPortfolio. Dan and his team are developing human monoclonal antibodies targeting 饾槇饾槫饾槳饾槸饾槮饾樀饾槹饾槪饾槩饾槫饾樀饾槮饾槼 饾槪饾槩饾樁饾槷饾槩饾槸饾槸饾槳饾槳.
PACE
@PACE_AMR
Pathways to Antimicrobial Clinical Efficacy. Accelerating and strengthening the pre-clinical AMR pipeline.
@LifeArc1 | @InnovateUK | @MedDiscCat
@LifeArc1 | @InnovateUK | @MedDiscCat
60 Following 143 Followers 136 Posts
Latest posts 5
We are at ESCMID Global 2025 in Vienna, Austria! R&D Advisors, Lisa Dawson and Jon Gibson, are representing PACE, so please do talk to them and find out what we are doing to support the AMR R&D community.
#ESCMIDGlobal2025
#ESCMIDGlobal2025
馃數 Our Programme Director, Dr Beverley Isherwood was recently interviewed by Helen Albert for Inside Precision Medicine. Read about how PACE is supporting early-stage innovation to help tackle AMR.
eu1.hubs.ly/H0j970n0
#AMR
@MedDiscCat | @innovateuk | @lifearc1
eu1.hubs.ly/H0j970n0
#AMR
@MedDiscCat | @innovateuk | @lifearc1
Congratulations to @immunethep!
We are delighted to announce that Immunethep has joined the PACE portfolio. Immunethep is advancing monoclonal antibodies to restore the ability to control bacterial infection. (1/2)
We are delighted to announce that Immunethep has joined the PACE portfolio. Immunethep is advancing monoclonal antibodies to restore the ability to control bacterial infection. (1/2)
Meet our PACE Delivery Partners! Innovators require support to accelerate antimicrobial & diagnostic discovery. Our Delivery Partner Network (DPN) connects providers with innovators to help with outsourced work & advice for PACE-funded projects.
馃敆: eu1.hubs.ly/H0hkL-Q0
(1/2)
馃敆: eu1.hubs.ly/H0hkL-Q0
(1/2)
1:09